Evidence map›Paper›PMID 25177338›Full record

ArticleNephron extra2014

The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells.

Joyce Geelen, Maartje van den Biggelaar, Peter Linssen, Thea van der Velden, Koen Mertens, Leo Monnens

Open access · goldAbstract read
In one paragraph

Article in Nephron extra, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Joyce GeelenDepartment of Paediatric Nephrology, The Netherlands.
Maartje van den BiggelaarDepartment of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands ; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
Peter LinssenCentral Hematology Laboratory, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Thea van der VeldenDepartment of Paediatric Nephrology, The Netherlands.
Koen MertensDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
Leo MonnensDepartment of Paediatric Nephrology, The Netherlands.
Pediatric Nephrology of Alabama · USPharmo Institute · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsDiarrhea-associated hemolytic uremic syndrome is associated with the presence of Shiga toxin (Stx1, Stx2 and several variants) in the circulation. The aim of this study is to examine the possible triggering effect of Stx1 on the exocytosis of Weibel-Palade bodies (WPbs).

methodsCultured human umbilical venous endothelial cells (HUVECs) and glomerular microvascular endothelial cells (GMVECs) were stimulated by thrombin and Stx1 in both static and flowing conditions. The amount of secreted von Willebrand factor (VWF) in the supernatant as well as the remaining intracellular fraction was determined.

resultsIn HUVECs and in 2 out of 4 GMVECs, the stimulation of Stx1 in flow at 1 dyne/cm(2) resulted in a decrease of intracellular VWF. This is contrary to the results of Stx1 applied in static conditions. At a higher flow rate of 5 dyne/cm(2), no effect in GMVECs was observed.

conclusionStx1 can contribute, via an effect on WPbs, to the exocytosis of WPbs in flow conditions in HUVECs and probably in GMVECs. This results in the release of VWF, suggesting an initiating role of the coagulation system in the pathogenesis.

Indexed as

Endothelial cellsShiga toxinvon Willebrand factorWeibel-Palade bodies

Identifiers

PMID25177338
PMCPMC4130816
OpenAlexW2157281245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.